Enhertu + THP before surgery resulted in a pathologic complete response in high-risk HER2+ early-stage breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Positive results from the DESTINY-Breast11 phase III trial showed Enhertu (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab, and pertuzumab in the neoadjuvant setting demonstrated a statistically significant and clinically meaningful improvement in the pathologic complete response rate. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

FDA approved Wilserdly (giredestrant) in combination with everolimus for the treatment of adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, whose disease has recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login